PharmaVoice Logo

Healthcare Leaders Hub

Immutep Reports Disease-Free Survival Data from the P-II (EFTISARC-NEO) Trial of Eftilagimod Alfa for Soft Tissue Sarcoma at CTOS 2026 | PharmaVoice